Eli Lilly and Company Company Profile (NYSE:LLY)

About Eli Lilly and Company (NYSE:LLY)

Eli Lilly and Company logoEli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company's human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists. Its animal health business segment operates through the Company's Elanco division, which develops, manufactures and markets products for both food animals and companion animals. The Company's human pharmaceutical products include endocrinology products, neuroscience products, oncology products, immunology products and cardiovascular products. The Company's animal health products segment includes products for food animals and products for companion animals. As of December 31, 2016, the Company manufactured and distributed its products through facilities in the United States, Puerto Rico and 14 other countries.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Pharmaceuticals - NEC
  • Sub-Industry: Pharmaceuticals
  • Symbol: NYSE:LLY
  • CUSIP: 53245710
  • Web: www.lilly.com
Capitalization:
  • Market Cap: $91.60335 billion
  • Outstanding Shares: 1,056,300,000
Average Prices:
  • 50 Day Moving Avg: $82.91
  • 200 Day Moving Avg: $81.37
  • 52 Week Range: $64.18 - $86.72
P/E:
  • Trailing P/E Ratio: 40.18
  • Foreward P/E Ratio: 18.51
  • P/E Growth: 1.70
Sales & Book Value:
  • Annual Revenue: $21.59 billion
  • Price / Sales: 4.07
  • Book Value: $13.28 per share
  • Price / Book: 6.26
Dividend:
  • Annual Dividend: $2.08
  • Dividend Yield: 2.5%
Profitability:
  • EBIDTA: $5.64 billion
  • Net Margins: 11.12%
  • Return on Equity: 28.50%
  • Return on Assets: 10.95%
Debt:
  • Debt-to-Equity Ratio: 0.54%
  • Current Ratio: 1.24%
  • Quick Ratio: 0.86%
Misc:
  • Average Volume: 3.70 million shs.
  • Beta: 0.35
  • Short Ratio: 2.62
 
Frequently Asked Questions for Eli Lilly and Company (NYSE:LLY)

What is Eli Lilly and Company's stock symbol?

Eli Lilly and Company trades on the New York Stock Exchange (NYSE) under the ticker symbol "LLY."

How often does Eli Lilly and Company pay dividends? What is the dividend yield for Eli Lilly and Company?

Eli Lilly and Company announced a quarterly dividend on Monday, June 19th. Investors of record on Tuesday, August 15th will be paid a dividend of $0.52 per share on Friday, September 8th. This represents a $2.08 annualized dividend and a yield of 2.50%. The ex-dividend date is Friday, August 11th. View Eli Lilly and Company's Dividend History.

How were Eli Lilly and Company's earnings last quarter?

Eli Lilly and Company (NYSE:LLY) posted its earnings results on Tuesday, July, 25th. The company reported $1.11 earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of $1.05 by $0.06. The firm earned $5.82 billion during the quarter, compared to analysts' expectations of $5.60 billion. Eli Lilly and Company had a net margin of 11.12% and a return on equity of 28.50%. Eli Lilly and Company's revenue was up 7.8% on a year-over-year basis. During the same period in the previous year, the company earned $0.86 earnings per share. View Eli Lilly and Company's Earnings History.

When will Eli Lilly and Company make its next earnings announcement?

Eli Lilly and Company is scheduled to release their next quarterly earnings announcement on Tuesday, October, 24th 2017. View Earnings Estimates for Eli Lilly and Company.

What guidance has Eli Lilly and Company issued on next quarter's earnings?

Eli Lilly and Company issued an update on its FY17 earnings guidance on Tuesday, July, 25th. The company provided earnings per share (EPS) guidance of $4.10-4.20 for the period, compared to the Thomson Reuters consensus EPS estimate of $4.12. The company issued revenue guidance of $22.0-22.5 billion, compared to the consensus revenue estimate of $22.15 billion.

Where is Eli Lilly and Company's stock going? Where will Eli Lilly and Company's stock price be in 2017?

18 brokerages have issued 12-month target prices for Eli Lilly and Company's stock. Their forecasts range from $73.00 to $100.00. On average, they expect Eli Lilly and Company's share price to reach $89.29 in the next twelve months. View Analyst Ratings for Eli Lilly and Company.

What are analysts saying about Eli Lilly and Company stock?

Here are some recent quotes from research analysts about Eli Lilly and Company stock:

  • 1. According to Zacks Investment Research, "Lilly’s presence across a wide range of therapeutic areas and its animal health business provide support in the face of generic competition. Lilly also expects some established products like Trajenta, Forteo and Humalog to continue doing well. Lilly expects to launch 20 new products between 2014 and 2023, including the launch of at least two new indications/line extensions on an average every year. The stock has risen this year, outperforming the return from the large cap pharma industry. However, Alimta will continue to be impacted by competition. Other headwinds include competition from immuno-oncology agents as well as loss of exclusivity for many drugs in the emerging markets. Meanwhile, the recent high-profile pipeline setbacks are an investor concern. Estimates have risen slightly ahead of the company’s Q2 release. The company has a mixed record of earnings surprises in recent quarters. " (7/17/2017)
  • 2. Jefferies Group LLC analysts commented, "Date and time of first dissemination: July 17, 2017, 08:17 ET Date and time of production: July 17, 2017, 08:17 ET Target Price / Valuation Methodology: Mallinckrodt plc – MNK Our discounted cash flow (DCF) analysis leads us to a price target of $87/share for MNK shares. Our DCF considers our estimates through 2027, slowing growth through 2033 and a 10% terminal decline thereafter. In addition, we expect Mallinckrodt’s margin structure to remain somewhat consistent with our 2027 estimates. We estimate a weighted average cost of capital (WACC) of 11.4% which is in line with other companies in Mallinckrodt’s peer set due to the company’s manageable leverage and consistent cash generation potential." (7/13/2017)
  • 3. UBS AG analysts commented, "We adjust our model to account for two months of reported IMS Rx data. Key growth drivers such as Trulicity and Taltz have performed better than expected while Basaglar (insulin glargine) was modestly lower than anticipated. Our overall 2017 revenues are largely unchanged as better than expected sales (largely from the Taltz and Trulicity) offset softer than expected sales of other products, and our 2017 EPS of $4.15 remain unchanged. For 2018, our revenues went up ~$70M largely driven by Taltz and we raise our EPS to $4.45 from $4.40." (3/20/2017)

Who are some of Eli Lilly and Company's key competitors?

Who are Eli Lilly and Company's key executives?

Eli Lilly and Company's management team includes the folowing people:

  • David A. Ricks, Chairman of the Board, President, Chief Executive Officer
  • Derica W. Rice, Chief Financial Officer, Executive Vice President - Global Services
  • Jan M. Lundberg Ph.D., Executive Vice President - Science and Technology, President - Lilly Research Laboratories
  • Melissa Stapleton Barnes, Senior Vice President - Enterprise Risk Management and Chief Ethics and Compliance Officer
  • Michael J. Harrington, Senior Vice President, General Counsel
  • Stephen F. Fry, Senior Vice President - Human Resources and Diversity
  • Enrique A. Conterno, Senior Vice President and President - Lilly Diabetes and President - Lilly USA
  • Susan Mahony Ph.D., Senior Vice President and President - Lilly Oncology
  • Barton R. Peterson, Senior Vice President - Corporate Affairs and Communications
  • Leigh Ann Pusey, Senior Vice President - Corporate Affairs and Communications

Who owns Eli Lilly and Company stock?

Eli Lilly and Company's stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Lilly Endowment Inc. (11.76%), Bessemer Group Inc. (0.30%), Fisher Asset Management LLC (0.28%), Beutel Goodman & Co Ltd. (0.24%), US Bancorp DE (0.22%) and State of New Jersey Common Pension Fund D (0.18%). Company insiders that own Eli Lilly and Company stock include Alfonso G Zulueta, David A Ricks, Derica W Rice, Donald A Zakrowski, Enrique A Conterno, Jackson P Tai, Lilly Endowment Inc, Maria A Crowe, Melissa S Barnes, Michael J Harrington, R David Hoover, Stephen F Fry and Susan Mahony. View Institutional Ownership Trends for Eli Lilly and Company.

Who sold Eli Lilly and Company stock? Who is selling Eli Lilly and Company stock?

Eli Lilly and Company's stock was sold by a variety of institutional investors in the last quarter, including Lilly Endowment Inc., APG Asset Management N.V., Barometer Capital Management Inc., NN Investment Partners Holdings N.V., Great West Life Assurance Co. Can, Rothschild Asset Management Inc., Forsta AP Fonden and Bedrijfstakpensioenfonds Voor DE Media PNO. Company insiders that have sold Eli Lilly and Company stock in the last year include Alfonso G Zulueta, Derica W Rice, Donald A Zakrowski, Enrique A Conterno, Lilly Endowment Inc, Maria A Crowe, Melissa S Barnes, Michael J Harrington and Susan Mahony. View Insider Buying and Selling for Eli Lilly and Company.

Who bought Eli Lilly and Company stock? Who is buying Eli Lilly and Company stock?

Eli Lilly and Company's stock was acquired by a variety of institutional investors in the last quarter, including Harbour Capital Advisors LLC, Bank of Montreal Can, Fisher Asset Management LLC, Beutel Goodman & Co Ltd., Mn Services Vermogensbeheer B.V., National Pension Service, Atalanta Sosnoff Capital LLC and Handelsbanken Fonder AB. Company insiders that have bought Eli Lilly and Company stock in the last two years include Jackson P Tai and R David Hoover. View Insider Buying and Selling for Eli Lilly and Company.

How do I buy Eli Lilly and Company stock?

Shares of Eli Lilly and Company can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Eli Lilly and Company's stock price today?

One share of Eli Lilly and Company stock can currently be purchased for approximately $83.10.


MarketBeat Community Rating for Eli Lilly and Company (NYSE LLY)
Community Ranking:  2.9 out of 5 ( )
Outperform Votes:  641 (Vote Outperform)
Underperform Votes:  470 (Vote Underperform)
Total Votes:  1,111
MarketBeat's community ratings are surveys of what our community members think about Eli Lilly and Company and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Eli Lilly and Company (NYSE:LLY) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 1 Sell Rating, 6 Hold Ratings, 11 Buy Ratings
Consensus Rating:Buy (Score: 2.56)
Consensus Price Target: $89.29 (7.45% upside)

Analysts' Ratings History for Eli Lilly and Company (NYSE:LLY)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
7/27/2017Berenberg BankReiterated RatingBuy$100.00LowView Rating Details
7/26/2017Oppenheimer Holdings, Inc.DowngradeOutperform -> Market Perform$90.00 -> $90.00LowView Rating Details
7/26/2017BMO Capital MarketsReiterated RatingUnderperform$73.00LowView Rating Details
7/26/2017Leerink SwannDowngradeOutperform -> Market Perform$93.00 -> $90.00LowView Rating Details
7/17/2017Deutsche Bank AGReiterated RatingBuy$90.00 -> $91.00LowView Rating Details
7/13/2017Jefferies Group LLCReiterated RatingBuy$93.00 -> $96.00LowView Rating Details
7/4/2017Citigroup Inc.Reiterated RatingBuy$100.00LowView Rating Details
7/4/2017Barclays PLCBoost Price TargetOverweight$85.00 -> $90.00LowView Rating Details
5/21/2017Sanford C. BernsteinReiterated RatingOutperform$88.00MediumView Rating Details
5/16/2017Goldman Sachs Group, Inc. (The)Reiterated RatingConviction-Buy -> Buy$92.00HighView Rating Details
4/27/2017ArgusDowngradeBuy -> Hold$64.18 -> $81.00LowView Rating Details
4/19/2017Credit Suisse GroupReiterated RatingOutperform$87.00LowView Rating Details
4/17/2017Piper Jaffray CompaniesReiterated RatingBuy$100.00MediumView Rating Details
4/17/2017Cowen and CompanyBoost Price TargetOutperform$85.00 -> $95.00MediumView Rating Details
4/17/2017Morgan StanleyDowngradeOverweight -> Equal Weight$82.00HighView Rating Details
11/26/2016J P Morgan Chase & CoReiterated RatingOverweightN/AView Rating Details
11/25/2016Atlantic SecuritiesDowngradeOverweight -> NeutralN/AView Rating Details
10/27/2016Societe GeneraleReiterated RatingHold$78.00N/AView Rating Details
6/15/2016SunTrust Banks, Inc.Reiterated RatingBuyN/AView Rating Details
12/22/2015Bank of America CorporationReiterated RatingBuy$104.00 -> $108.00N/AView Rating Details
(Data available from 7/29/2015 forward)

Earnings

Earnings History for Eli Lilly and Company (NYSE:LLY)
Earnings by Quarter for Eli Lilly and Company (NYSE:LLY)
Earnings History by Quarter for Eli Lilly and Company (NYSE LLY)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
10/24/2017$1.03N/AView Earnings Details
7/25/2017Q2 2017$1.05$1.11$5.60 billion$5.82 billionViewN/AView Earnings Details
4/25/2017Q1 17$0.96$0.98$5.22 billion$5.23 billionViewN/AView Earnings Details
1/31/2017Q416$0.98$0.95$5.54 billion$5.76 billionViewN/AView Earnings Details
10/25/2016Q316$0.96$0.88$4.23 billion$5.19 billionViewListenView Earnings Details
7/26/2016Q216$0.86$0.86$5.14 billion$5.40 billionViewListenView Earnings Details
4/26/2016Q116$0.85$0.83$4.82 billion$4.87 billionViewListenView Earnings Details
1/28/2016Q415$0.78$0.78$5.33 billion$5.38 billionViewListenView Earnings Details
10/22/2015Q315$0.76$0.89$4.99 billion$4.96 billionViewListenView Earnings Details
7/23/2015Q215$0.74$0.90$4.89 billion$4.98 billionViewListenView Earnings Details
4/23/2015Q115$0.76$0.87$4.62 billion$4.64 billionViewN/AView Earnings Details
1/30/2015Q414$0.74$0.75$5.21 billion$5.12 billionViewN/AView Earnings Details
10/23/2014Q314$0.66$0.66$4.83 billion$4.88 billionViewListenView Earnings Details
7/24/2014Q214$0.66$0.68$4.88 billion$4.94 billionViewN/AView Earnings Details
4/24/2014Q114$0.70$0.70$4.78 billion$4.68 billionViewN/AView Earnings Details
1/30/2014Q413$0.72$0.74$5.46 billion$5.81 billionViewListenView Earnings Details
10/23/2013Q313$1.04$1.11$5.76 billion$5.77 billionViewN/AView Earnings Details
7/24/2013Q2 2013$1.01$1.16$5.82 billion$5.93 billionViewN/AView Earnings Details
4/24/2013Q1 2013$1.05$1.14$5.66 billion$5.60 billionViewN/AView Earnings Details
1/29/2013Q4 2012$0.82$0.85$5.78 billion$5.96 billionViewN/AView Earnings Details
10/24/2012$0.82$0.79ViewN/AView Earnings Details
7/25/2012$0.76$0.83ViewN/AView Earnings Details
4/25/2012$0.80$0.92ViewN/AView Earnings Details
1/31/2012$0.80$0.87ViewN/AView Earnings Details
10/20/2011$1.12$1.13ViewN/AView Earnings Details
7/21/2011$1.18$1.18ViewN/AView Earnings Details
4/18/2011$1.16$1.24ViewN/AView Earnings Details
1/27/2011$1.10$1.11ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Eli Lilly and Company (NYSE:LLY)
2017 EPS Consensus Estimate: $4.11
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20172$0.98$0.98$0.98
Q2 20172$1.04$1.06$1.05
Q3 20172$1.03$1.06$1.05
Q4 20172$1.01$1.06$1.04
(Data provided by Zacks Investment Research)

Dividends

Current Dividend Information for Eli Lilly and Company (NYSE:LLY)
Next Dividend:9/8/2017
Annual Dividend:$2.08
Dividend Yield:2.50%
Dividend Growth:1.30% (3 Year Average)
Payout Ratio:90.04% (Trailing 12 Months of Earnings)
50.12% (Based on This Year's Estimates)
46.33% (Based on Next Year's Estimates)
Track Record:2 Years of Consecutive Dividend Growth
Dividend Payments by Quarter for Eli Lilly and Company (NYSE:LLY)

Dividend History by Quarter for Eli Lilly and Company (NYSE LLY)
AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
6/19/2017quarterly$0.522.51%8/11/20178/15/20179/8/2017
5/1/2017quarterly$0.522.55%5/11/20175/15/20176/9/2017
12/13/2016quarterly$0.523.03%2/13/20172/15/20173/10/2017
10/17/2016quarterly$0.512.59%11/10/201611/15/201612/9/2016
6/20/2016quarterly$0.512.81%8/11/20168/15/20169/9/2016
5/2/2016quarterly$0.512.68%5/11/20165/13/20166/10/2016
12/8/2015quarterly$0.512.43%2/10/20162/12/20163/10/2016
10/19/2015quarterly$0.502.57%11/10/201511/13/201512/10/2015
6/15/2015quarterly$0.502.42%8/12/20158/14/20159/10/2015
5/4/2015quarterly$0.502.78%5/14/20155/18/20156/10/2015
12/15/2014quarterly$0.502.89%2/11/20152/13/20153/10/2015
10/20/2014quarterly$0.493.03%11/12/201411/14/201412/10/2014
6/16/2014quarterly$0.493.31%8/13/20148/15/20149/10/2014
5/5/2014quarterly$0.493.35%5/13/20145/15/20146/10/2014
12/16/2013quarterly$0.493.98%2/12/20142/14/20143/10/2014
10/21/2013quarterly$0.493.91%11/13/201311/15/201312/10/2013
6/18/2013quarterly$0.493.82%8/13/20138/15/20139/10/2013
5/6/2013quarterly$0.493.62%5/14/20135/16/20136/10/2013
12/17/2012quarterly$0.493.96%2/13/20132/15/20133/8/2013
(Data available from 1/1/2013 forward)

Insider Trades

Insider Trading and Institutional Ownership History for Eli Lilly and Company (NYSE:LLY)
Insider Ownership Percentage: 0.20%
Institutional Ownership Percentage: 75.56%
Insider Trades by Quarter for Eli Lilly and Company (NYSE:LLY)
Institutional Ownership by Quarter for Eli Lilly and Company (NYSE:LLY)
Insider Trades by Quarter for Eli Lilly and Company (NYSE:LLY)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
6/22/2017Lilly Endowment IncMajor ShareholderSell210,000$84.43$17,730,300.00View SEC Filing  
6/20/2017Lilly Endowment IncMajor ShareholderSell215,000$83.05$17,855,750.00View SEC Filing  
6/12/2017Melissa S BarnesInsiderSell1,900$80.78$153,482.00View SEC Filing  
6/9/2017Michael J HarringtonVPSell22,833$79.97$1,825,955.01View SEC Filing  
5/4/2017Enrique A ConternoSVPSell25,000$82.76$2,069,000.00View SEC Filing  
3/30/2017Lilly Endowment IncMajor ShareholderSell210,000$84.67$17,780,700.00View SEC Filing  
2/17/2017Lilly Endowment IncMajor ShareholderSell230,000$80.27$18,462,100.00View SEC Filing  
2/6/2017Alfonso G ZuluetaSVPSell15,000$77.66$1,164,900.00View SEC Filing  
2/3/2017Derica W RiceEVPSell11,162$77.14$861,036.68View SEC Filing  
2/2/2017Donald A ZakrowskiInsiderSell2,000$77.52$155,040.00View SEC Filing  
2/1/2017Lilly Endowment IncMajor ShareholderSell220,000$77.35$17,017,000.00View SEC Filing  
12/16/2016Lilly Endowment IncMajor ShareholderSell200,000$72.59$14,518,000.00View SEC Filing  
12/16/2016Melissa S BarnesInsiderSell2,093$82.23$172,107.39View SEC Filing  
12/16/2016R David HooverDirectorBuy500$71.85$35,925.00View SEC Filing  
12/16/2016Susan MahonySVPSell20,242$72.65$1,470,581.30View SEC Filing  
10/5/2016Maria A CroweInsiderSell2,248$81.37$182,919.76View SEC Filing  
8/15/2016Jackson P TaiDirectorBuy5,773$80.43$464,322.39View SEC Filing  
8/12/2016Jackson P TaiDirectorBuy2,560$80.42$205,875.20View SEC Filing  
7/29/2016Lilly Endowment IncMajor ShareholderSell205,000$82.94$17,002,700.00View SEC Filing  
7/28/2016Donald A ZakrowskiInsiderSell1,213$83.16$100,873.08View SEC Filing  
7/28/2016Lilly Endowment IncMajor ShareholderSell240,000$82.87$19,888,800.00View SEC Filing  
7/12/2016Lilly Endowment IncMajor ShareholderSell210,000$79.54$16,703,400.00View SEC Filing  
7/7/2016Lilly Endowment IncMajor ShareholderSell225,000$79.14$17,806,500.00View SEC Filing  
6/30/2016Lilly Endowment IncMajor ShareholderSell215,000$78.46$16,868,900.00View SEC Filing  
6/29/2016Lilly Endowment IncMajor ShareholderSell220,000$77.86$17,129,200.00View SEC Filing  
6/10/2016Melissa S BarnesSVPSell992$73.77$73,179.84View SEC Filing  
5/31/2016Lilly Endowment IncMajor ShareholderSell200,000$75.12$15,024,000.00View SEC Filing  
5/12/2016Jackson P TaiDirectorBuy1,080$75.75$81,810.00View SEC Filing  
5/12/2016Lilly Endowment IncMajor ShareholderSell190,000$75.86$14,413,400.00View SEC Filing  
5/2/2016Donald A ZakrowskiCAOSell1,600$75.86$121,376.00View SEC Filing  
4/29/2016Lilly Endowment IncMajor ShareholderSell180,000$75.44$13,579,200.00View SEC Filing  
4/27/2016Alfonso G ZuluetaSVPSell12,000$76.27$915,240.00View SEC Filing  
4/8/2016Lilly Endowment IncMajor ShareholderSell200,000$74.29$14,858,000.00View SEC Filing  
2/5/2016Stephen F FrySVPSell15,230$78.87$1,201,190.10View SEC Filing  
2/3/2016David A. RicksSVPSell5,733$77.66$445,224.78View SEC Filing  
2/3/2016Derica W. RiceCFOSell10,483$77.78$815,367.74View SEC Filing  
2/1/2016Jackson P TaiDirectorBuy3,170$78.62$249,225.40View SEC Filing  
1/29/2016Alfonso G ZuluetaSVPSell5,000$78.75$393,750.00View SEC Filing  
12/21/2015Lilly Endowment IncMajor ShareholderSell205,000$86.00$17,630,000.00View SEC Filing  
12/15/2015Lilly Endowment IncMajor ShareholderSell215,000$85.60$18,404,000.00View SEC Filing  
12/9/2015Enrique A ConternoVPSell25,000$83.88$2,097,000.00View SEC Filing  
12/2/2015Lilly Endowment Incmajor shareholderSell210,000$85.09$17,868,900.00View SEC Filing  
11/20/2015Lilly Endowment Incmajor shareholderSell205,000$84.54$17,330,700.00View SEC Filing  
10/29/2015Lilly Endowment Incmajor shareholderSell200,000$82.28$16,456,000.00View SEC Filing  
10/9/2015Lilly Endowment Incmajor shareholderSell215,000$85.86$18,459,900.00View SEC Filing  
10/5/2015Lilly Endowment Incmajor shareholderSell260,000$86.46$22,479,600.00View SEC Filing  
9/18/2015Lilly Endowment Incmajor shareholderSell250,000$89.04$22,260,000.00View SEC Filing  
6/10/2015Lilly Endowment IncMajor ShareholderSell210,000$82.39$17,301,900.00View SEC Filing  
6/4/2015Lilly Endowment IncMajor ShareholderSell200,000$77.90$15,580,000.00View SEC Filing  
5/29/2015Jeffrey N SimmonsSVPSell20,000$78.08$1,561,600.00View SEC Filing  
5/20/2015Lilly Endowment IncMajor ShareholderSell190,000$73.43$13,951,700.00View SEC Filing  
5/15/2015Lilly Endowment IncMajor ShareholderSell200,000$72.83$14,566,000.00View SEC Filing  
5/8/2015Lilly Endowment IncMajor ShareholderSell195,000$73.28$14,289,600.00View SEC Filing  
5/1/2015Lilly Endowment IncMajor ShareholderSell200,000$73.09$14,618,000.00View SEC Filing  
3/30/2015Lilly Endowment IncMajor ShareholderSell180,000$73.94$13,309,200.00View SEC Filing  
3/23/2015Lilly Endowment IncMajor ShareholderSell190,000$76.97$14,624,300.00View SEC Filing  
3/9/2015Stephen F FrySVPSell4,000$69.27$277,080.00View SEC Filing  
2/4/2015David A RicksSVPSell3,147$69.99$220,258.53View SEC Filing  
2/4/2015Derica W RiceCFOSell5,316$70.00$372,120.00View SEC Filing  
2/4/2015Jan M LundbergEVPSell11,085$70.08$776,836.80View SEC Filing  
2/3/2015Jan M LundbergEVPSell121,711$70.78$8,614,704.58View SEC Filing  
2/2/2015David A RicksSVPSell4,769$71.51$341,031.19View SEC Filing  
2/2/2015Derica W RiceCFOSell10,068$71.84$723,285.12View SEC Filing  
12/4/2014Lilly Endowment IncMajor ShareholderSell190,000$71.92$13,664,800.00View SEC Filing  
12/2/2014Lilly Endowment IncMajor ShareholderSell180,000$70.14$12,625,200.00View SEC Filing  
11/13/2014Lilly Endowment IncMajor ShareholderSell200,000$67.73$13,546,000.00View SEC Filing  
11/5/2014Lilly Endowment IncMajor ShareholderSell180,000$67.00$12,060,000.00View SEC Filing  
11/4/2014Fionnuala M WalshSVPSell15,000$67.00$1,005,000.00View SEC Filing  
11/3/2014Enrique A ConternoVPSell5,000$66.03$330,150.00View SEC Filing  
10/31/2014Fionnuala M WalshSVPSell7,376$66.58$491,094.08View SEC Filing  
10/31/2014Lilly Endowment IncMajor ShareholderSell190,000$66.40$12,616,000.00View SEC Filing  
10/30/2014Lilly Endowment IncMajor ShareholderSell175,000$66.58$11,651,500.00View SEC Filing  
10/24/2014Maria A CroweInsiderSell2,750$65.77$180,867.50View SEC Filing  
10/6/2014Lilly Endowment IncMajor ShareholderSell210,000$65.63$13,782,300.00View SEC Filing  
10/1/2014Enrique A ConternoVPSell5,000$64.86$324,300.00View SEC Filing  
9/30/2014Lilly Endowment IncMajor ShareholderSell200,000$65.07$13,014,000.00View SEC Filing  
9/10/2014Lilly Endowment IncMajor ShareholderSell210,000$64.77$13,601,700.00View SEC Filing  
9/3/2014Lilly Endowment IncMajor ShareholderSell200,000$63.99$12,798,000.00View SEC Filing  
9/2/2014Enrique A ConternoVPSell5,000$63.60$318,000.00View SEC Filing  
7/29/2014Lilly Endowment IncMajor ShareholderSell250,000$63.03$15,757,500.00View SEC Filing  
7/28/2014Susan MahonySVPSell2,065$63.30$130,714.50View SEC Filing  
7/25/2014Enrique A ConternoVPSell10,000$63.79$637,900.00View SEC Filing  
7/25/2014Susan MahonySVPSell30,000$63.90$1,917,000.00View SEC Filing  
7/1/2014Lilly Endowment IncMajor ShareholderSell235,000$62.30$14,640,500.00View SEC Filing  
6/25/2014Lilly Endowment IncMajor ShareholderSell245,000$62.68$15,356,600.00View SEC Filing  
6/20/2014Lilly Endowment IncMajor ShareholderSell230,000$61.55$14,156,500.00View SEC Filing  
6/16/2014Lilly Endowment IncMajor ShareholderSell200,000$58.73$11,746,000.00View SEC Filing  
6/5/2014Lilly Endowment IncMajor ShareholderSell190,000$59.53$11,310,700.00View SEC Filing  
5/21/2014Lilly Endowment Incmajor shareholderSell230,000$58.90$13,547,000.00View SEC Filing  
5/12/2014Jackson TaiDirectorBuy17,157$59.19$1,015,522.83View SEC Filing  
5/12/2014Lilly Endowment Incmajor shareholderSell210,000$59.33$12,459,300.00View SEC Filing  
5/6/2014Lilly Endowment Incmajor shareholderSell190,000$58.79$11,170,100.00View SEC Filing  
4/29/2014Lilly Endowment Incmajor shareholderSell200,000$59.43$11,886,000.00View SEC Filing  
4/28/2014Lilly Endowment Incmajor shareholderSell150,000$58.64$8,796,000.00View SEC Filing  
8/15/2013Enrique ConternoVPSell5,000$53.79$268,950.00View SEC Filing  
7/29/2013Jacques TapieroSVPSell7,500$53.74$403,050.00View SEC Filing  
7/15/2013Enrique A ConternoVPSell5,000$51.43$257,150.00View SEC Filing  
6/17/2013Enrique A ConternoVPSell5,000$52.45$262,250.00View SEC Filing  
5/15/2013Enrique A ConternoVPSell5,000$56.15$280,750.00View SEC Filing  
5/10/2013Jeffrey N SimmonsSVPSell10,000$54.49$544,900.00View SEC Filing  
3/26/2013Susan MahonySVPSell5,000$56.00$280,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Eli Lilly and Company (NYSE:LLY)
Latest Headlines for Eli Lilly and Company (NYSE:LLY)
Source:
DateHeadline
finance.yahoo.com logoPfizer on the Street: Inside the Analysts’ Recommendations
finance.yahoo.com - July 29 at 2:33 AM
finance.yahoo.com logoEli Lilly’s 2Q17 Earnings Rose 8% Year-over-Year
finance.yahoo.com - July 29 at 2:33 AM
finance.yahoo.com logoEli Lilly’s Business Segments in 2Q17
finance.yahoo.com - July 29 at 2:33 AM
finance.yahoo.com logoDow's Merck Crushed Keytruda Sales Views By $68 Million
finance.yahoo.com - July 29 at 2:33 AM
finance.yahoo.com logoEli Lilly in 2Q17: Performance of New Products
finance.yahoo.com - July 29 at 2:33 AM
americanbankingnews.com logoEli Lilly and Company (LLY) to Post FY2019 Earnings of $4.61 Per Share, Leerink Swann Forecasts
www.americanbankingnews.com - July 28 at 7:24 PM
americanbankingnews.com logoFY2018 EPS Estimates for Eli Lilly and Company Cut by Jefferies Group (LLY)
www.americanbankingnews.com - July 28 at 6:33 PM
americanbankingnews.com logoQ3 2017 EPS Estimates for Eli Lilly and Company (LLY) Lowered by SunTrust Banks
www.americanbankingnews.com - July 28 at 11:01 AM
finance.yahoo.com logoDiabetes Crisis Continues To Rage, But Biopharma's Response Is Tepid
finance.yahoo.com - July 28 at 2:18 AM
americanbankingnews.com logoFY2017 Earnings Estimate for Eli Lilly and Company (LLY) Issued By Jefferies Group
www.americanbankingnews.com - July 27 at 9:59 AM
americanbankingnews.com logoBrokers Set Expectations for Eli Lilly and Company's Q3 2017 Earnings (NYSE:LLY)
www.americanbankingnews.com - July 27 at 8:44 AM
benzinga.com logoIntense Competition Pressures Eli Lilly, Leerink Downgrades
www.benzinga.com - July 27 at 4:01 AM
finance.yahoo.com logoFeatured Company News - Eli Lilly and Nektar Announce Agreement to Co-Develop NKTR-358, the Self-Administered Injection for a Number of Autoimmune Disease
finance.yahoo.com - July 27 at 4:01 AM
finance.yahoo.com logoKey Takeaways from Lilly's (LLY) Q2 Call: Baricitinib, Cancer Pipeline
finance.yahoo.com - July 27 at 4:01 AM
finance.yahoo.com logoZoetis Investors May Need Patience To See Bull Thesis Play Out
finance.yahoo.com - July 27 at 4:01 AM
finance.yahoo.com logoEli Lilly: The Competition is Just Too Darn Intense!
finance.yahoo.com - July 27 at 4:01 AM
americanbankingnews.com logoEli Lilly and Company (NYSE:LLY) Lifted to B+ at TheStreet
www.americanbankingnews.com - July 26 at 9:18 PM
americanbankingnews.com logoEli Lilly and Company (NYSE:LLY) Rating Lowered to Market Perform at Oppenheimer Holdings, Inc.
www.americanbankingnews.com - July 26 at 2:40 PM
americanbankingnews.com logoEli Lilly and Company (NYSE:LLY) Receives "Underperform" Rating from BMO Capital Markets
www.americanbankingnews.com - July 26 at 12:41 PM
bloomberg.com logoLilly Continues to Test Investor Belief - Bloomberg
www.bloomberg.com - July 26 at 4:05 AM
seekingalpha.com logoLilly Hopes To Bloom Through Nektar Attraction - Seeking Alpha
seekingalpha.com - July 26 at 4:05 AM
seekingalpha.com logoEli Lilly & Co. (LLY) Q2 2017 Results - Earnings Call Transcript - Seeking Alpha
seekingalpha.com - July 26 at 4:05 AM
finance.yahoo.com logoEli Lilly CEO Reiterates 5% Revenue Growth Target
finance.yahoo.com - July 25 at 11:00 PM
finance.yahoo.com logoLilly signals long delay for arthritis drug, shares fall
finance.yahoo.com - July 25 at 11:00 PM
finance.yahoo.com logo3 Buy-Ranked Stocks That Just Crushed Earnings
finance.yahoo.com - July 25 at 11:00 PM
finance.yahoo.com logoEdited Transcript of LLY earnings conference call or presentation 25-Jul-17 1:00pm GMT
finance.yahoo.com - July 25 at 11:00 PM
finance.yahoo.com logoLilly beats Street 2Q forecasts
finance.yahoo.com - July 25 at 11:00 PM
cnbc.com logoEli Lilly CEO expects a Trump executive order on drug pricing this year
www.cnbc.com - July 25 at 2:56 PM
americanbankingnews.com logoEli Lilly and Company (NYSE:LLY) Updates FY17 Earnings Guidance
www.americanbankingnews.com - July 25 at 10:39 AM
americanbankingnews.com logoEli Lilly and Company (NYSE:LLY) Posts Earnings Results, Beats Estimates By $0.06 EPS
www.americanbankingnews.com - July 25 at 9:58 AM
seekingalpha.com logoEli Lilly Q2 revenues up 8%; non-GAAP EPS up 29%; revises 2017 guidance
seekingalpha.com - July 25 at 8:34 AM
nasdaq.com logoEli Lilly Agrees With Nektar To Co-Develop NKTR - 358
www.nasdaq.com - July 25 at 2:54 AM
News IconBRIEF-Eli Lilly and Nektar Therapeutics to develop, commercialize NKTR-358
www.businessinsider.com - July 25 at 2:54 AM
seekingalpha.com logoEarnings Preview: What Might Be Expected From Caterpillar, Eli Lilly And General Motors?
seekingalpha.com - July 25 at 2:54 AM
finance.yahoo.com logoHow Merck’s Animal Health Business Is Expected to Perform in 2017
finance.yahoo.com - July 25 at 2:54 AM
finance.yahoo.com logoWhat Analysts Recommend for Eli Lilly ahead of 2Q17 Results
finance.yahoo.com - July 25 at 2:54 AM
finance.yahoo.com logoFDA tentatively approves Merck's copycat of Sanofi's Lantus (July 20)
finance.yahoo.com - July 25 at 2:54 AM
marketbeat.com logoHasbro and Hibbett sink as WebMD and Nektar climb
marketbeat.com - July 24 at 5:06 PM
marketwatch.com logoEli Lilly will co-develop autoimmune disease therapy under $150 million deal with Nektar - MarketWatch
www.marketwatch.com - July 24 at 11:38 AM
finance.yahoo.com logoNektar Therapeutics surges 10% on $150 mln Eli Lilly deal
finance.yahoo.com - July 24 at 11:38 AM
finance.yahoo.com logoBig Pharma Q2 Earnings Releases on Jul 25: LLY, BIIB, AMGN
finance.yahoo.com - July 24 at 11:38 AM
finance.yahoo.com logoWhat Analysts Predict for Eli Lilly’s 2Q17 Earnings
finance.yahoo.com - July 24 at 11:37 AM
finance.yahoo.com logoWhy Eli Lilly Expects 2Q17 Revenue Growth
finance.yahoo.com - July 24 at 11:37 AM
finance.yahoo.com logoCould This Small Biotech Break Out On A Tie-Up With Eli Lilly?
finance.yahoo.com - July 24 at 11:37 AM
finance.yahoo.com logoEli Lilly will co-develop autoimmune disease therapy under $150 million deal with Nektar
finance.yahoo.com - July 24 at 11:37 AM
americanbankingnews.com logoZacks: Brokerages Anticipate Eli Lilly and Company (LLY) Will Post Quarterly Sales of $5.59 Billion
www.americanbankingnews.com - July 20 at 10:35 AM
nasdaq.com logoIs a Beat in the Cards for Eli Lilly (LLY) in Q2 Earnings? - Nasdaq
www.nasdaq.com - July 20 at 12:24 AM
finance.yahoo.com logoIs a Beat in the Cards for Eli Lilly (LLY) in Q2 Earnings?
finance.yahoo.com - July 20 at 12:24 AM
americanbankingnews.com logoFY2020 EPS Estimates for Eli Lilly and Company Lowered by SunTrust Banks (LLY)
www.americanbankingnews.com - July 19 at 3:46 PM
americanbankingnews.com logoEli Lilly and Company (LLY) Expected to Post Earnings of $1.03 Per Share
www.americanbankingnews.com - July 19 at 12:16 AM

Social

Chart

Eli Lilly and Company (LLY) Chart for Saturday, July, 29, 2017

This page was last updated on 7/29/2017 by MarketBeat.com Staff